JAK2 and MPL Screening Profile

Description
Human myeloproliferative disorders form a range of clonal haematological malignant diseases, the main constituents being Polycythaemia Vera (PV), Essential Thrombocytopenia (ET) and Idiopathic Myelofibrosis (MF). They are a heterogeneous group of diseases characterised by excessive production of blood cells by haemopoietic precursors. JAK2V617F is an exon 14 somatic mutation (G to T) resulting in the substitution of valine to phenylalanine at codon 617. JAK2V617F mutations are associated with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis PMF. MPL mutations are associated with MPNs are restricted to patients with PMF or ET. The ability to routinely assess both JAK2 and MPL mutations would be beneficial in the differential diagnosis of unexplained thrombocytosis or myelofibrosis.
Clinical details
JAK2V617F mutations are associated with MPNs, including PV, ET and PMF. MPL mutations are restricted to patients with PMF or ET. The ability to routinely assess both JAK2 and MPL mutations would be beneficial in the differential diagnosis of unexplained thrombocytosis or myelofibrosis.
Related condition
Reference range
Whole Blood.
Synonyms
MPD, Myelorpoliferative disorder, PV, Polycythaemia ET, Essential Thrombocytopenia, MF, Myelofibrosis, JAK2V617F, CALR, MPL, Calrectulin.
Testing site
Synnovis : Genomics : Guy's Hospital
Laboratory
Cancer Genetics
Sample type and volume required
20ml peripheral blood in EDTA.
Special sample instructions
Samples should reach the laboratory within 24 hours of being taken.
Storage and transport
Room temperature. Samples should reach the laboratory within 24 hours of being taken.
Turnaround time
2 weeks.

Last updated:

Back to search